Starting Your Journey with Penile Cancer
At a Glance
Penile cancer is a rare disease that typically develops as squamous cell carcinoma through HPV or chronic inflammatory pathways. Patients achieve the best outcomes by seeking treatment at high-volume specialist centers that offer phallus-preserving surgery and expert lymph node management.
If you have recently been diagnosed with penile cancer, you may feel a profound sense of shock, fear, or isolation. It is important to know that these feelings are a normal reaction to a diagnosis that is both rare and highly personal. Because this condition is uncommon, you may not know anyone else who has gone through it, but there is a clear path forward and a specialized community of experts dedicated to your care.
Understanding a Rare Diagnosis
Penile cancer is quite rare. Globally, it affects approximately 0.84 people out of every 100,000 annually [1]. Because it is so infrequent, many local urologists may only see one or two cases in their entire career.
Most penile cancers—about 95%—are a type called Squamous Cell Carcinoma (SCC) [2]. This means the cancer begins in the squamous cells, which are the thin, flat skin cells that make up the surface of the penis [2].
For more details on how to identify the early warning signs and avoid being misdiagnosed with a simple infection, see our guide on Recognizing Symptoms and Avoiding Misdiagnosis.
The Two Pathways of Development
Medical research has identified two primary biological “pathways” or ways that penile cancer typically develops. Knowing which pathway your cancer followed can help your doctors determine the most effective approach for you.
- The HPV-Driven Pathway: This pathway is caused by an infection with the Human Papillomavirus (HPV) [3]. In these cases, the virus causes changes in the skin cells over time that lead to cancer. Generally, patients with HPV-driven cancer may have slightly better survival outcomes [4][5].
- The HPV-Independent Pathway: This pathway is not related to a virus. Instead, it is often linked to chronic (long-term) inflammation of the skin [6]. Two common conditions associated with this pathway are:
Cancers that develop through this second, HPV-independent pathway can sometimes behave more aggressively [4][10]. To learn more about the specific sub-types of this cancer, read Biological Pathways and Cancer Subtypes.
Decoding Your Diagnosis
Your diagnosis will be accompanied by a complex pathology report outlining your “TNM Stage” and tumor grade. Understanding whether the cancer has invaded the corpus spongiosum versus the corpus cavernosum, or if it has reached your lymph nodes, is critical for your next steps. Use our Decoding Your Pathology and Staging Report guide to audit your own records.
Why Specialist Care Matters
Because penile cancer is so rare, the “gold standard” for treatment is to seek care at a high-volume specialist center [11]. These are large hospitals or cancer centers where surgeons and oncologists see many cases of penile cancer every year.
Research shows that patients treated at these specialized centers often have better results [11][12]. The benefits of a specialist center include:
- Expertise in Preservation: Specialists are often more experienced in phallus-preserving surgery, which aims to remove the cancer while keeping as much healthy tissue and function as possible [11].
- Precise Lymph Node Management: Managing the inguinal lymph nodes (the nodes in your groin) is a critical part of treatment. Specialists are highly skilled in determining if the cancer has spread to these nodes and performing the necessary procedures with fewer complications [13][14].
- Multidisciplinary Teams: Your care will likely involve a team of urologists, radiation oncologists, and medical oncologists who collaborate on a single, personalized plan [12][15].
To understand your surgical and non-surgical options, review the Standard Treatment and Specialist Care page.
If your local doctor has not treated many cases of penile cancer, it is entirely appropriate—and often recommended—to ask for a referral to a major academic medical center or a specialist who focuses on urologic oncology. Once treatment is complete, lifelong monitoring is essential to ensure the cancer does not return, which is covered in Life After Treatment: Monitoring and Well-being.
In this guide
5 chapters
Recognizing Symptoms and Avoiding Misdiagnosis
Learn the early warning signs of penile cancer, common misdiagnoses like fungal infections, and why a biopsy is critical if symptoms don't heal in 2-3 weeks.
Biological Pathways and Cancer Subtypes
Learn about the different subtypes of penile cancer. Understand HPV-associated vs. HPV-independent pathways, p16 testing, and what they mean for your care.
Decoding Your Pathology and Staging Report
Learn how to read your penile cancer pathology report. Understand AJCC T-staging, tumor grade, LVI, and nodal status to guide your treatment decisions.
Standard Treatment and Specialist Care
Learn about standard treatments for penile cancer, including organ-preserving surgery, radiation therapy, and lymph node management at high-volume centers.
Life After Treatment: Monitoring and Well-being
Learn what to expect during penile cancer survivorship. Understand follow-up exam schedules, how to perform self-exams, and ways to manage your well-being.
Common questions in this guide
Is penile cancer always caused by HPV?
What is the most common type of penile cancer?
Why should I see a specialist for penile cancer?
Does having penile cancer mean I will lose my penis?
How do doctors know if the cancer has spread?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How many patients with penile cancer do you treat each year?
- 2.Has my tumor been tested for p16 or HPV status, and how does that influence my outlook?
- 3.Do I have signs of lichen sclerosus or other chronic inflammatory conditions?
- 4.Is my case being reviewed by a multidisciplinary tumor board?
- 5.Will you be checking my inguinal lymph nodes, and what is the plan for monitoring them?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Incidence of penile cancer worldwide: systematic review and meta-analysis.
Montes Cardona CE, García-Perdomo HA
Revista panamericana de salud publica = Pan American journal of public health 2017; (41()):e117 doi:10.26633/RPSP.2017.117.
PMID: 31384255 - 2
The Main Genetic-Molecular Aspects of Penile Cancer.
Hurtado R, Zender-Poma G, Wang L, Tirado CA
Journal of the Association of Genetic Technologists 2024; (50(1)):14-18.
PMID: 38447205 - 3
Penile cancer.
Thomas A, Necchi A, Muneer A, et al.
Nature reviews. Disease primers 2021; (7(1)):11 doi:10.1038/s41572-021-00246-5.
PMID: 33574340 - 4
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis.
Mustasam A, Parza K, Ionescu F, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(2)).
PMID: 39752880 - 5
Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer.
Ulvskog E, Kirrander P, Persson EK, et al.
European urology open science 2025; (79()):102-110 doi:10.1016/j.euros.2025.07.012.
PMID: 40822998 - 6
Transcriptionally Active Human Papillomavirus in Male Genital Lichen Sclerosus, Penile Intraepithelial Neoplasia, and Penile Squamous Cell Carcinoma.
Kravvas G, Xie B, Haider A, et al.
JID innovations : skin science from molecules to population health 2025; (5(1)):100320 doi:10.1016/j.xjidi.2024.100320.
PMID: 39758591 - 7
Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study.
Gu W, Zhang P, Zhang G, et al.
Frontiers in oncology 2020; (10()):1521 doi:10.3389/fonc.2020.01521.
PMID: 33014796 - 8
The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients.
Kravvas G, Shim TN, Doiron PR, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(1)):91-95 doi:10.1111/jdv.14488.
PMID: 28750140 - 9
Lichen Sclerosus-Incidence and Comorbidity: A Nationwide Swedish Register Study.
Jerkovic Gulin S, Lundin F, Eriksson O, Seifert O
Journal of clinical medicine 2024; (13(10)) doi:10.3390/jcm13102761.
PMID: 38792303 - 10
Penile Cancers Attributed to Human Papillomavirus Are Associated with Improved Survival for Node-positive Patients. Findings from a Norwegian Cohort Study Spanning 50 Years.
Moen CA, Falkenthal TE, Thorkelsen TK, et al.
European urology oncology 2024; (7(4)):778-785 doi:10.1016/j.euo.2023.10.013.
PMID: 37949729 - 11
Phallus preservation and reconstruction: 5-year outcomes of national penile cancer centralisation in the Republic of Ireland.
Hogan D, Norton SM, Patterson K, et al.
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2024; (22(5)):292-295 doi:10.1016/j.surge.2024.04.002.
PMID: 38614838 - 12
Centralization and Equitable Care in Rare Urogenital Malignancies: The Case for Penile Cancer.
Jakobsen JK, Pettaway CA, Ayres B
European urology focus 2021; (7(5)):924-928 doi:10.1016/j.euf.2021.09.019.
PMID: 34593356 - 13
Centralization of Penile Cancer Management in the United States: A Combined Analysis of the American Board of Urology and National Cancer Data Base.
Matulewicz RS, Flum AS, Helenowski I, et al.
Urology 2016; (90()):82-8.
PMID: 26827845 - 14
Impact of Examined Lymph Node Count and Lymph Node Density on Overall Survival of Penile Cancer.
Gao P, Zhu T, Gao J, et al.
Frontiers in oncology 2021; (11()):706531 doi:10.3389/fonc.2021.706531.
PMID: 34307174 - 15
Immune-based therapies in penile cancer.
Joshi VB, Spiess PE, Necchi A, et al.
Nature reviews. Urology 2022; (19(8)):457-474 doi:10.1038/s41585-022-00617-x.
PMID: 35851333
This page provides general information about penile cancer diagnosis and pathways for educational purposes. Always consult an experienced urologic oncologist to discuss your specific staging, treatment options, and medical care.
Get notified when new evidence is published on Malignant tumor of penis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.